• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫检查点治疗应答者表现出肿瘤浸润淋巴细胞的早期克隆扩增。

Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.

机构信息

National Centre for Asbestos Related Diseases, Institute for Respiratory Health, University of Western Australia, Perth, Australia.

Telethon Kids Institute, Perth, Australia.

出版信息

Oncoimmunology. 2024 Apr 26;13(1):2345859. doi: 10.1080/2162402X.2024.2345859. eCollection 2024.

DOI:10.1080/2162402X.2024.2345859
PMID:38686178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11057660/
Abstract

Immune checkpoint therapy (ICT) causes durable tumour responses in a subgroup of patients, but it is not well known how T cell receptor beta (TCRβ) repertoire dynamics contribute to the therapeutic response. Using murine models that exclude variation in host genetics, environmental factors and tumour mutation burden, limiting variation between animals to naturally diverse TCRβ repertoires, we applied TCRseq, single cell RNAseq and flow cytometry to study TCRβ repertoire dynamics in ICT responders and non-responders. Increased oligoclonal expansion of TCRβ clonotypes was observed in responding tumours. Machine learning identified TCRβ CDR3 signatures unique to each tumour model, and signatures associated with ICT response at various timepoints before or during ICT. Clonally expanded CD8+ T cells in responding tumours post ICT displayed effector T cell gene signatures and phenotype. An early burst of clonal expansion during ICT is associated with response, and we report unique dynamics in TCRβ signatures associated with ICT response.

摘要

免疫检查点疗法(ICT)可使一部分患者的肿瘤持久消退,但 T 细胞受体β(TCRβ)谱系动力学如何促进治疗反应尚不清楚。我们使用排除了宿主遗传、环境因素和肿瘤突变负担变化的鼠模型,将动物之间的变化限制为自然存在的多样化 TCRβ 谱系,应用 TCRseq、单细胞 RNAseq 和流式细胞术研究 ICT 应答者和非应答者的 TCRβ 谱系动力学。在应答肿瘤中观察到 TCRβ 克隆型的寡克隆扩增增加。机器学习为每个肿瘤模型确定了独特的 TCRβ CDR3 特征,以及在 ICT 之前或期间的各个时间点与 ICT 反应相关的特征。ICT 后应答肿瘤中克隆扩增的 CD8+T 细胞显示效应 T 细胞基因特征和表型。ICT 期间早期的克隆扩增与反应相关,我们报告了与 ICT 反应相关的 TCRβ 特征的独特动态。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/c87fe2754cc3/KONI_A_2345859_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/14ebe7562f8d/KONI_A_2345859_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/d49312b45bdc/KONI_A_2345859_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/cd5922708ea9/KONI_A_2345859_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/02e8f0b721d6/KONI_A_2345859_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/d2f39b5874b8/KONI_A_2345859_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/c87fe2754cc3/KONI_A_2345859_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/14ebe7562f8d/KONI_A_2345859_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/d49312b45bdc/KONI_A_2345859_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/cd5922708ea9/KONI_A_2345859_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/02e8f0b721d6/KONI_A_2345859_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/d2f39b5874b8/KONI_A_2345859_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a8f/11057660/c87fe2754cc3/KONI_A_2345859_F0006_OC.jpg

相似文献

1
Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.免疫检查点治疗应答者表现出肿瘤浸润淋巴细胞的早期克隆扩增。
Oncoimmunology. 2024 Apr 26;13(1):2345859. doi: 10.1080/2162402X.2024.2345859. eCollection 2024.
2
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.检查点阻断免疫疗法增强了小鼠肿瘤浸润 T 细胞的频率和效应功能,但不改变 TCRβ 多样性。
Cancer Immunol Immunother. 2019 Jul;68(7):1095-1106. doi: 10.1007/s00262-019-02346-4. Epub 2019 May 18.
3
T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients.肿瘤浸润淋巴细胞的 T 细胞受体谱来自乳腺癌患者的体外扩增。
Immunol Res. 2020 Oct;68(5):233-245. doi: 10.1007/s12026-020-09150-8. Epub 2020 Aug 28.
4
Tumor Infiltrating Effector Memory Antigen-Specific CD8 T Cells Predict Response to Immune Checkpoint Therapy.肿瘤浸润效应记忆抗原特异性 CD8 T 细胞预测免疫检查点治疗反应。
Front Immunol. 2020 Nov 12;11:584423. doi: 10.3389/fimmu.2020.584423. eCollection 2020.
5
Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4 and CD8 T-cell clusters in systemic sclerosis.纵向分析 T 细胞受体库揭示了系统性硬化症中抗原驱动的 CD4 和 CD8 T 细胞簇的持续存在。
J Autoimmun. 2021 Feb;117:102574. doi: 10.1016/j.jaut.2020.102574. Epub 2020 Dec 8.
6
Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.预先存在的效应 T 细胞水平和增强的髓样细胞组成预示着激素受体阳性转移性乳腺癌对 CDK4/6 抑制剂 palbociclib 和 pembrolizumab 的反应。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002084.
7
Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders.宿主特异性 TCR 克隆型的扩展与抗 PD-L1 治疗在应答者与无应答者中的不同结局相关。
Front Immunol. 2023 Mar 27;14:1100520. doi: 10.3389/fimmu.2023.1100520. eCollection 2023.
8
Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.放疗和 CTLA-4 阻断塑造肿瘤浸润 T 细胞的 TCR 库。
Cancer Immunol Res. 2018 Feb;6(2):139-150. doi: 10.1158/2326-6066.CIR-17-0134. Epub 2017 Nov 27.
9
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.PD-1 鉴定了浸润人类肿瘤的患者特异性 CD8⁺ 肿瘤反应性免疫组库。
J Clin Invest. 2014 May;124(5):2246-59. doi: 10.1172/JCI73639. Epub 2014 Mar 25.
10
Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.TCR repertoire 和 T 细胞激活的差异是抗肿瘤免疫反应在清除肿瘤宿主和进展肿瘤宿主中产生不同结果的基础。
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001615.

引用本文的文献

1
Machine learning in oncological pharmacogenomics: advancing personalized chemotherapy.肿瘤药理学中的机器学习:推进个性化化疗。
Funct Integr Genomics. 2024 Oct 4;24(5):182. doi: 10.1007/s10142-024-01462-4.
2
Exploiting temporal aspects of cancer immunotherapy.挖掘癌症免疫疗法的时间维度。
Nat Rev Cancer. 2024 Jul;24(7):480-497. doi: 10.1038/s41568-024-00699-2. Epub 2024 Jun 17.

本文引用的文献

1
Evolution and modulation of antigen-specific T cell responses in melanoma patients.黑色素瘤患者中抗原特异性 T 细胞反应的进化和调节。
Nat Commun. 2022 Oct 11;13(1):5988. doi: 10.1038/s41467-022-33720-z.
2
Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy.深度学习揭示免疫组库中对免疫疗法具有预测性的序列概念。
Sci Adv. 2022 Sep 16;8(37):eabq5089. doi: 10.1126/sciadv.abq5089.
3
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice.时间限制的 IFNβ 信号激活是小鼠对免疫检查点治疗产生应答的基础。
Nat Commun. 2022 Aug 19;13(1):4895. doi: 10.1038/s41467-022-32567-8.
4
Proportional Tumor Infiltration of T Cells Circulation Duplicates the T Cell Receptor Repertoire in a Bilateral Tumor Mouse Model.双侧肿瘤小鼠模型中 T 细胞循环浸润比例复制了 T 细胞受体库。
Front Immunol. 2021 Oct 25;12:744381. doi: 10.3389/fimmu.2021.744381. eCollection 2021.
5
Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 T cell clone size and cytotoxicity.免疫检查点阻断敏感性和无进展生存期与基线 CD8 T 细胞克隆大小和细胞毒性相关。
Sci Immunol. 2021 Oct;6(64):eabj8825. doi: 10.1126/sciimmunol.abj8825. Epub 2021 Oct 1.
6
DOME: recommendations for supervised machine learning validation in biology.DOME:生物学中监督式机器学习验证的建议
Nat Methods. 2021 Oct;18(10):1122-1127. doi: 10.1038/s41592-021-01205-4.
7
The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival.肿瘤浸润 T 细胞的 T 细胞受体谱可预测和预测癌症的生存情况。
Nat Commun. 2021 Jul 2;12(1):4098. doi: 10.1038/s41467-021-24343-x.
8
Gene Set Knowledge Discovery with Enrichr.基因集知识发现与 Enrichr
Curr Protoc. 2021 Mar;1(3):e90. doi: 10.1002/cpz1.90.
9
DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires.DeepTCR 是一个深度学习框架,用于揭示 T 细胞受体库中的序列概念。
Nat Commun. 2021 Mar 11;12(1):1605. doi: 10.1038/s41467-021-21879-w.
10
Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment.通过在肿瘤微环境中进行基于腺相关病毒载体和程序性死亡受体1(PD1)的疫苗接种来消除间皮瘤。
Mol Ther Oncolytics. 2021 Jan 21;20:373-386. doi: 10.1016/j.omto.2021.01.010. eCollection 2021 Mar 26.